Evidence map›Paper›PMID 42857545›Full record

ArticleACS organic & inorganic Au2026

Process Development toward DHODH Inhibitor JNJ-6665.

Kangying Li, Edward Cleator, Simon Wagschal, Shane Plunkett, Yanfeng Jin, Zhi Liu, Baoqing Gong, Jeff Grimm, William Maton, Matthieu Jouffroy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS organic & inorganic Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kangying LiJohnson & Johnson (China) Investment Ltd. Beijing Branch 14F, Tower 3, China Central Place, No.77, Jianguo Road, Chaoyang District, Beijing 100025, P. R. China.
Edward CleatorJanssen Pharmaceutica NV, a Johnson & Johnson Company, Turnhoutseweg 30, 2340 Beerse, Belgium.
Simon WagschalChemical Process Research and Development, Janssen Pharmaceutica, Hochstrasse 201, Schaffhausen 8200, Switzerland.ORCID https://orcid.org/0000-0003-1979-5838
Shane PlunkettChemical Process Research and Development, Janssen R&D, Raritan, New Jersey 08869, United States.ORCID https://orcid.org/0000-0002-5825-8085
Yanfeng JinPharmaron Beijing Co., Ltd. (China), 6 Taihe Road, BDA, Beijing 100176, P. R. China.
Zhi LiuJanssen (China) R&D Center, 16 F, Building A, Xinyan Mansion, No. 65, Guiqing Road, Shanghai 200030, P. R. China.
Baoqing GongJohnson & Johnson (China) Investment Ltd. Beijing Branch 14F, Tower 3, China Central Place, No.77, Jianguo Road, Chaoyang District, Beijing 100025, P. R. China.
Jeff GrimmChemical Process Research and Development, Janssen R&D, Raritan, New Jersey 08869, United States.
William MatonJanssen Pharmaceutica NV, a Johnson & Johnson Company, Turnhoutseweg 30, 2340 Beerse, Belgium.
Matthieu JouffroyJanssen Pharmaceutica NV, a Johnson & Johnson Company, Turnhoutseweg 30, 2340 Beerse, Belgium.ORCID https://orcid.org/0000-0003-4478-2502

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

JNJ-6665 is a dihydroorotate dehydrogenase (DHODH) inhibitor progressed for first-in-human studies. We developed a convergent, chromatography-free manufacturing route leveraging a regioselective SNAr coupling of triazolone

Indexed as

DHODHPd-catalyzed α-arylationphase-transfer catalysis (PTC)process developmenttelescoped steps

Identifiers

PMID42857545
PMCPMC13650944

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.